Tyra Biosciences is a US biopharmaceutical company that develops therapies for cancer patients by targeting fibroblast growth factor receptors (FGFRs), with the aim of overcoming tumor resistance. The company's lead candidate is TYRA-300, a selective FGFR3 inhibitor for muscle invasive bladder cancer. Additionally, it uses a molecular SNAPshots platform for creating rapid structural designs.